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Abstract
Background: FTO and NAMPT/PBEF/visfatin are thought to play a role in obesity but their transcriptional regulation in
adipocytes is not fully understood. In this study, we evaluated the transcriptional regulation of FTO and NAMPT in
preadipocytes and adipocytes by metabolic regulators.
Methodology and Principal Findings: We assessed FTO mRNA expression during human adipocyte differentiation of
Simpson-Golabi-Behmel syndrome (SGBS) cells and primary subcutaneous preadipocytes in vitro and evaluated the effect of
the metabolic regulators glucose, insulin, dexamethasone, IGF-1 and isoproterenol on FTO and NAMPT mRNA expression in
SGBS preadipocytes and adipocytes. FTO mRNA levels were not significantly modulated during adipocyte differentiation.
Also, metabolic regulators had no impact on FTO expression in preadipocytes or adipocytes. In SGBS preadipocytes NAMPT
expression was more than 3fold induced by dexamethasone and isoproterenol and 1.6fold by dexamethasone in
adipocytes. Complete glucose restriction caused an increase in NAMPT mRNA expression by more than 5fold and 1.4fold in
SGBS preadipocytes and adipocytes, respectively.
Conclusion: FTO mRNA expression is not significantly affected by differentiation or metabolic regulators in human
adipocytes. The stimulation of NAMPT expression by dexamethasone, isoproterenol and complete glucose restriction may
indicate a regulation of NAMPT by metabolic stress, which was more pronounced in preadipocytes compared to mature
adipocytes.
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Introduction
Previously, various genes including the fat mass and obesity
associated (FTO) and the nicotinamide phosphoribosyltransferase (NAMPT)
gene have been suggested to potentially contribute to the
development of obesity and related metabolic traits [1,2]. Several
independent genetic association studies have associated variants in
the FTO gene with predisposition to childhood and adult obesity
[1,3,4]. The location of the variants in intron 1 of the FTO gene
may indicate a putative effect on gene transcription regulation. Of
interest, FTO variant rs8050136, located ,270-kb proximal to
FTO [5], was demonstrated to influence retinoblastoma-like 2
(RBL2) gene expression. RBL2 is a key regulator of entry into cell
division that may also play a role in adipogenesis [6]. FTO is
widely expressed in human fetal and adult tissues, particularly the
brain [1]. In addition, expression in metabolically active tissues
such as skeletal muscle, liver and adipose tissue has been reported
[7,8]. It has also been demonstrated that inactivation of the FTO
gene in mice reduced white adipose tissue mass and adipocyte size,
and protected from diet induced obesity [9]. In addition to
potential central effects on food intake [10,11], FTO has been
described to affect body fat mass through regulation of lipolysis
[12]. In vitro studies and crystal structure analyses suggested a
DNA/RNA demethylase function for FTO as a potential
mechanism [13–15]. Furthermore, a recent publication identified
FTO as a transcriptional coactivator enhancing the transactivation
potential of CCAAT/enhancer binding proteins [16] that are
master regulators of adipogenesis. Together, these findings support
a functional role for FTO in the development of obesity on the
central and/or peripheral level. So far, there are only sparse data
on how metabolic factors might modulate FTO expression in
adipose tissue.
NAMPT, also known as pre B-cell colony enhancing factor or
‘‘visfatin’’, is another novel obesity related factor and has been
shown to play a role in glucose homeostasis [17]. The mRNA
expression and protein release of NAMPT has been reported, in
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murine adipocytes [18] and THP-1 monocytes [19]. In addition, a
differential regulation of NAMPT expression by dexamethasone
and isoproterenol in murine 3T3-L1 adipocytes has been reported
[20]. We have previously shown that NAMPT expression is higher
in adipocytes compared to preadipocytes [17] and is associated
with glucose metabolism [21]. However, a putative distinct
modulation of NAMPT transcription by metabolic regulators in
human preadipocytes compared to adipocytes still remains to be
elucidated.
Taken together, data from the literature suggest that FTO and
NAMPT represent two novel candidates potentially involved in
the pathophysiology of obesity and associated metabolic disorders.
The regulation of these two factors in adipocytes remains less
clear. We, therefore, aimed to evaluate FTO expression during
human adipocyte differentiation to assess whether the association
of FTO with obesity may be directly related to adipogenesis.
Furthermore, we investigated a potential transcriptional regulation
of FTO and NAMPT in preadipocytes and adipocytes by metabolic
regulators.
Materials and Methods
Cell culture of preadipocytes and adipocytes
Experiments were performed using the Simpson-Golabi-Behmel
syndrome (SGBS) cell model which was a generous gift from M.
Wabitsch (Ulm, Germany). Cells were cultured in basal SGBS
medium consisting of DMEM/Ham F12 medium (Life Technol-
ogies, Karlsruhe, Germany) supplemented with 33 mM biotin and
17 mM pantothenic acid. Cells were differentiated into mature
adipocytes as previously described [22]. Briefly, SGBS preadipo-
cytes were grown to confluence in basal medium supplemented
with 10% FCS. Adipocyte differentiation was induced under
serum-free conditions by supplementing basal medium with
20 nM insulin, 0.2 nM triiodothyronine, 100 nM hydrocortisone,
and 0.13 nM apo-transferrin. For the first 4 days of differentiation,
2 mM rosiglitazone, 25 nM dexamethasone and 500 mM3 -
isobutyl-1-methylxanthine (IBMX) were additionally added. Cells
were harvested every other day from day 0 to day 12 post-
induction. Human subcutaneous preadipocytes from three male
individuals (Caucasian, 21–60 years old, non-diabetic) were
purchased from LONZA (Walkersville, USA) and were cultured
and differentiated according to the manufacturer’s instructions.
Cells were harvested every other day from day 0 to day 12 post-
induction.
Stimulation with metabolic regulators
Stimulation experiments were performed in SGBS preadipo-
cytes and mature adipocytes at day 10 post-induction under
serum-free conditions. Confluent preadipocytes were serum
starved for 24 h and then cultivated in SGBS basal medium
supplemented with either 100 nM insulin or 100 nM dexameth-
asone, 100 nM IGF-1 or 10 mM isoproterenol for additional 24 h
for. For stimulation experiments in adipocytes we applied two
different experimental approaches: i) the adipocyte cell medium
was directly replaced by basal SGBS medium containing
respective stimulants (see above) for 24 h (unstarved from
adipogenic supplements) and ii) adipocytes were starved from
adipogenic supplements in SGBS basal medium for 24 h prior to
stimulation. Untreated cells incubated in basal SGBS medium for
24 h served as control (C). For stimulation with D-glucose the cell
culture medium was replaced by DMEM adjusted to 0, 2.2, 4.4,
8.8, 17.5 or 35 mM D-glucose and supplemented with 33 mM
biotin and 17 mM pantothenic acid for 48 h. Preadipocytes and
adipocytes cultured for 48 h in DMEM adjusted to 17.5 mM
glucose, which is consistent with the glucose concentration in basal
SGBS medium, served as control.
Analysis of mRNA expression
Total RNA was extracted using the RNeasy Mini Kit (Qiagen,
Hilden, Germany) according to the manufacturer’s instructions.
Reverse transcription was performed using 200 U M-MLV
reverse transcriptase per 500 ng total RNA (Invitrogen, Karlsruhe,
Germany) with random hexamer [p(dN)6] primers. FTO, RBL2,
NAMPT and peroxisome proliferator-activated receptor c (PPARc) mRNA
expression was quantified by real-time PCR with TaqMan probe-
based gene expression assay on the ABI 7500 Sequence Detection
System (Applied Biosystems, Darmstadt, Germany). The house-
keeping genes Hypoxanthine-guanine phosphoribosyltransferase (HPRT),
ß-actin (ACTB), and TATA-box-binding protein (TBP) were quantified
simultaneously. Sequence information of primers and probes is
given in the Table 1. For standardization of gene expression target
genes were normalized to the mean of the three housekeeping
genes. Basal expression of FTO, RBL2, NAMPT and PPARc in
preadipocytes (d0), in untreated cells (C) or in cells incubated in
17.5 mM glucose was set 1.
Statistical analyses
Data are presented as means 6 SEM of at least 3 independent
cell culture experiments, each performed in triplicates. Expression
during adipogenesis was analyzed applying one-way ANOVA with
repeated measurements and Dunnett’s post test. The differences
between means in stimulation experiments were analyzed by
Student t-test. The threshold for statistical significance was set at
P,0.05. Statistical analyses were performed using Graph Pad
Prism 4 (GraphPad Software Inc., San Diego, CA, USA).
Results
FTO expression during adipogenesis
We first evaluated, whether FTO mRNA expression is
modulated during human adipocyte differentiation. Over the
differentiation period of 12 days, FTO mRNA levels remained
unchanged in the SGBS cell model (Figure 1A) as well as in
primary (pre)adipocytes (Figure 1B). The 20fold increase of PPARc
expression confirmed an effective adipocyte differentiation and
was similar in both cell models. Hence, FTO mRNA expression is
not significantly modulated during differentiation and maturation
of human adipocytes. Similar to FTO, RBL2 expression was not
transcriptionally regulated during adipogenesis (Figure 1A+B).
FTO expression in response to metabolic regulators
In preadipocytes and adipocytes, insulin, dexamethasone, IGF-1
and isoproterenol had no effect on FTO mRNA expression
(Figure 2A+B). When adipocyte culture medium was not depleted
from adipogenic supplements (insulin, triiodothyronine, hydrocor-
tisone) 24 h prior to stimulation experiments, treatment of
adipocytes with 100 nM IGF-1 resulted in a moderate reduction
of FTO expression by 15.765.1% (P=0.03), while incubation with
insulin, dexamethasone and isoproterenol did not modulate FTO
mRNA level (data not shown). Altering glucose concentrations
did not affect FTO expression in preadipocytes or adipocytes
(Figure 2C+D).
NAMPT expression in response to metabolic regulators
NAMPT expression was significantly induced 3.260.5 fold by
dexamethasone and 3.360.9 fold by isoproterenol in preadipo-
cytes, while insulin and IGF-1 did not alter NAMPT mRNA levels
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was slightly diminished to 1.660.2 fold (Figure 3B). In adipocytes
cultured in medium that was not depleted from adipogenic
supplements 24 h prior to stimulation experiments, neither insulin,
IGF-1, dexamethasone, nor isoproterenol did affect NAMPT
mRNA expression (data not shown).
Increasing glucose concentrations had no impact on NAMPT
expression, but complete glucose restriction stimulated NAMPT
mRNA expression by 5.161.2 fold and 1.460.1 fold in
preadipocytes and adipocytes, respectively (Figure 3C+D).
Discussion
In this study, we evaluated the potential regulation of FTO and
NAMPT as two novel candidates potentially involved in the
pathophysiology of obesity and metabolic sequelae by metabolic
regulators at the level of adipocytes.
We show that expression of the ‘‘obesity gene’’ FTO is not
significantly affected by adipocyte differentiation or metabolic
regulators related to glucose and insulin metabolism in our cell
models of human subcutaneous adipocytes. Variants in the FTO
gene have been unequivocally and robustly associated with obesity
risk [1,3,4]. We hypothesized that FTO may be related to
adipogenesis and, therefore, evaluated FTO expression during
human adipocyte differentiation. FTO mRNA expression was,
however, not modulated during differentiation of preadipocytes
into mature adipocytes suggesting that FTO expression in
adipocytes may not be related to increasing adipose tissue mass.
Also, mRNA levels of RBL2, that was suggested to mediate the
biological consequences of a FTO variant on obesity risk [5],
remained unchanged. An increase of PPARc expression during
adipogenesis confirmed efficient adipocyte differentiation, hence
excluding a bias by suboptimal adipogenesis. Our results
somewhat contrast the findings of previous studies demonstrating
that FTO expression is decreased during differentiation of primary
preadipocytes isolated from human subcutaneous adipose tissue
[12] or SGBS preadipocytes [23]. The discrepancy might be
explained by differences in experimental protocols with respect to
exposure to adipogenic supplements. On the other hand, we and
others provided evidence that adipocyte aging is associated with a
reduction in gene expression of adiponectin, leptin and PPARc
after day 10–12 [24,25]. Hence, the reported decrease of FTO
expression at day 14 post induction in the study of Tews et al. [23]
might at least be attributed to the aging process. Nevertheless,
analyses were restricted to subcutaneous adipocytes so far; it has
been clearly demonstrated that subcutaneous and visceral
adipocytes exhibit differences in gene expression and metabolic
properties [26]. Thus, a putative differential regulation of FTO
during adipogenesis in adipocytes obtained from other fat depots
such as visceral adipose tissue still needs to be elucidated.
A potential role for FTO in the development of obesity was
proposed by studies in mice showing that Fto deficiency resulted in
reduced body weight and white adipose tissue mass [9,27].
Complete absence of Fto was also characterized by growth
retardation [9]. Considering that IGF-1 stimulates lipogenesis and
that FTO has been shown to increase lipolysis [12,28], one may
speculate that IGF-1 and FTO may counteract as metabolic
regulators in adipose tissue. Also, whole body and neural Fto
knockout mice have reduced serum levels of IGF-1 suggesting that
FTO regulates directly or indirectly IGF-1 secretion by the liver
Table 1. Sequences of primer and probes.
Gene Forward primer Reverse primer Probe
FTO TTGGCCGGTTCACAACCTC AGCCAACTGACAGCGTTGTAAA TCCTGTTGAGCACTCTGCCACTCGG
RBL2 TTGGCATGGAAACCAGAGTCT GCCAGCAATGCAAATTTCATC TTCCTACATGTGAAGAGGTCATGCCACCT
NAMPT GCAGAAGCCGAGTTCAACATC TGCTTGTGTTGGGTGGATATTG TGGCCACCGAACTCAC
PPARc GATCCAGTGGTTGCAGATTACAA GAGGGAGTTGGAAGGCTCTTC TGACCTGAAACTTCAAGAGTACCAAAGTGCAA
ACTB TGAGCGCGGCTACAGCTT CCTTAATGTCACGCACGATTT ACCACCACGGCCGAGCGG
TBP TTGTAAACTTGACCTAAAGACCATTGC TTCGTGGCTCTCTTATCCTCATG AACGCCGAATATAATCCCAAGC GGTTTG
HPRT GGCAGTATAATCCAAAGATGGTCAA GTCTGGCTTATATCCAACACTTCGT CAAGCTTGCTGGTGAAAAGGACCCC
doi:10.1371/journal.pone.0019526.t001
Figure 1. FTO and RBL2 expression during adipogenesis. FTO and
RBL2 expression was not modulated during in vitro differentiation of
SGBS (A) and primary subcutaneous (B) preadipocytes to mature
adipocytes (expression in preadipocytes at day 0 was set=1). An
expected increase in mRNA expression of PPARc confirmed efficient
adipogenesis. Data are shown for at least 3 independent cell
experiments. Statistical significance was assessed by ANOVA with
repeated measurements and Dunnett’s post test. Data are mean6SEM.
doi:10.1371/journal.pone.0019526.g001
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coactivator [16] via C/EBP binding to the IGF-1 promotor [30].
Together, this may point to a putative interaction of FTO and
IGF-1 in several tissues.
To further evaluate the interaction with metabolic regulators,
we investigated the impact of glucose, insulin as well as
dexamethasone and isoproterenol, representing exogenous com-
pounds that affect the stress axis, on FTO expression in
preadipocytes and adipocytes to mimic different metabolic states
of energy excess and energy deficiency in preadipocytes and
adipocytes. However, neither glucose or insulin nor dexametha-
sone or isoproterenol did affect FTO gene expression. Our results
hence indicate that nutritional status does not influence FTO
expression at the level of adipocytes in our models. FTO is widely
expressed across multiple tissues including adipose tissue, liver,
pancreas, and skeletal muscle. The highest abundance of FTO
mRNA was, however, found in the brain, particularly in the
hypothalamus [1,13]. Rodent studies revealed that FTO expres-
sion is nutritionally regulated in these hypothalamic regions
[13,31]. Furthermore, several studies in humans [32], rats [33]
and mice [9,29] indicated that FTO acts on the level of the central
nervous system mainly in the arcuate nucleus of hypothalamus.
Overall, these results indicate that the brain rather than
adipocytes are the primary site of FTO regulation by nutritional
status. But the regulation of FTO by metabolic factors in adipocytes
derived from different adipose tissue depots is still elusive.
NAMPT has been found to play an important role in the
regulation of glucose metabolism, primarily through effects on
beta cell function [17]. In adipocytes NAMPT has also been
shown to be affected by cytokines and hormones related to glucose
homeostasis in murine 3T3-L1 cells [20,34]. In our study, the
compounds that affect the stress axis, namely dexamethasone and
isoproterenol induced NAMPT expression in human preadipo-
cytes. In line with this, dexamethasone increased NAMPT mRNA
levels in murine 3T3-L1 adipocytes [20,35], while isoproterenol
decreased NAMPT expression in the murine model [20]. These
controversial results may reflect differences in the cell models and/
or species as has been shown for other adipocytokines [36].
Of interest, the effect of dexamethasone and isoproterenol on
NAMPT expression was more pronounced in preadipocytes
compared to adipocytes in our study. There are several possible
explanations for that. First, NAMPT is mildly increased during
adipogenesis [17,20,37] and the higher basal expression in mature
adipocytes and/or the supplement of dexamethasone for the
differentiation may have reduced responsiveness to the factors in
mature adipocytes. Second, changes in the gene expression pattern
during adipocyte differentiation [38] may also account for an
altered sensitivity of preadipocytes and adipocytes. Third,
preadipocytes are potentially more sensitive to distinct stress
stimuli than adipocytes as shown for LPS stimulated production of
cytokines such as IL-6, TNF-a, MCP-1 and IL-8 which was more
pronounced in preadipocytes than in adipocytes [39,40].
Considering that NAMPT release has been reported to be
enhanced by glucose in adipocytes [18], we expected an increase
of NAMPT with increasing glucose concentrations. However, high
glucose concentrations did not affect NAMPT mRNA levels.
Figure 2. FTO expression in response to metabolic regulators. Preadipocytes (A+C) and adipocytes (day 10 of differentiation) (B+D) were
stimulated with 100 nM insulin (Ins), 100 nM dexamethasone (Dex), 100 nM IGF-1 and 100 nM isoproterenol (Iso) for 24 h and with increasing
concentrations of glucose for 48 h as indicated. Expression in untreated cells (C) and at 17.5 mM glucose was set=1. Data are shown for 3
independent cell experiments. Statistical significance was assessed by student’s t-test.
doi:10.1371/journal.pone.0019526.g002
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gene expression. Again, this effect was more pronounced in
preadipocytes compared to adipocytes. Also other studies have
reported that NAMPT expression is induced by glucose restriction
and fasting [41,42]. Complete glucose deprivation induces
endoplasmic reticulum (ER) stress and cell death. As a NAD
biosynthetic enzyme, NAMPT is involved in the regulation of a
variety of biological processes, such as differentiation, metabolism
and stress response [43].We thus hypothesize that our results may
reflect an adaptive response to cellular stress due to reduced
nutrient availability [41,44].
In contrast to glucose, insulin had no effect on NAMPT
synthesis in our cell model, which is consistent with data from
studies in murine as well as primary human adipocytes [18,20].
Taken together, our data indicate that NAMPT expression in
subcutaneous adipocytes is not regulated by high insulin and
glucose concentrations that represent common features of insulin
resistance and type 2 diabetes. Interestingly, the stress axis
affecting compounds dexamethasone and isoproterenol, that are
known to induce insulin resistance in adipocytes [45,46] induced
NAMPT transcription. Our results indicate that NAMPT mRNA
levels are enhanced in response to cellular stress but appear to be
not regulated by nutrients in human adipocytes in vitro.
A potential limitation of our study is that the SGBS cell model is
a cell line that may not necessarily respond the same as normal
adipocytes. Hence, our results on action and regulation of FTO
and NAMPT can not be generalized to the level of adipose tissue.
In summary, we demonstrate that FTO gene expression is not
related to differentiation and maturation of human adipocytes.
Furthermore, we show that FTO expression is not regulated by
factors known to impact glucose metabolism. NAMPT expression
was induced by stress axis affecting compounds and complete
glucose restriction supporting a potential role in compensation of
cellular stress response in preadipocytes and adipocytes.
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